WORCESTER, Mass., Oct. 16, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that, at a conference earlier this week in Oran, Algeria, Generex, together with Continental Pharma Laboratories, the Company's importation, marketing, distribution, and sales agent in Algeria, announced the launch of commercial sales of Generex Oral-lyn(TM) in Algeria. The product has been approved for importation and commercial marketing and sale in Algeria, and will be marketed and sold for the treatment of patients with Type-1 or Type-2 diabetes. The size of the diabetes population in the Eastern Mediterranean and Middle East region is approximately 24,500,000.

The launch of Generex Oral-lyn(TM) took place at Royal Hotel, Oran. In addition to more than 100 endocrinologists and other healthcare providers in attendance, notable participants included:

 * Mr. AbdulGhani Benhalima, President of Continental Pharma
   Laboratories;
 * Mr. Bill Abajian, Sr. Executive Advisor, Global Licensing and
   Business Development, Generex Biotechnology Corporation;
 * Dr. Jamie Davidson, Medical Director, Generex Biotechnology
   Corporation;
 * Professor Mohamed Belhadj, M.D., President of Algerian Internal
   Medicine Society; and
 * Mr. Leo Ohanian, Managing Director, Generex Biotechnology
   Corporation MENA.

"It is with great enthusiasm that we launch Generex Oral-lyn(TM) in Algeria with our distribution partner, Continental Pharma Laboratories," said Mr. Abajian. "While we continue to make progress in the Middle Eastern theater, our second commercial launch in the region (Lebanon and now Algeria) will provide great exposure to our novel and unique drug product. Over the course of both launches, more than 200 endocrinologists have been educated about the application of Generex Oral-lyn(TM) and that figure will continue to grow as additional training sessions take place."

The Algerian pharmaceutical market is approximately 1.5 billion Euros annually. The population of the country is about 33,000,000 and according to the International Diabetes Federation, Algeria has a diabetic prevalence of about 7.5% of the population, or 2,475,000 people ages 20-79.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).